MarketWatch

AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4's Path to First- Patient Dosing

The MarketWatch News Department was not involved in the creation of this content. Dover, DE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned ...
Nasdaq

AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing ...

Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and ...
Hosted on MSN

AlphaTON Capital, Subsidiary Tarus Therapeutics Explore Tokenization of Mesothelioma Drug TT-4 Economics

AlphaTON Capital (ATON) said Wednesday together with its oncology unit Tarus Therapeutics they have signed a non-binding letter of intent to explore tokenization of economics for mesothelioma program ...
Nasdaq

AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

“ADDRI’s leadership in asbestos-related disease makes Australia a compelling setting for a TT-4 investigator-initiated trial,” said Peter Molloy, Chief Executive Officer, Cyncado Therapeutics. “We are ...
Hosted on MSN

AlphaTON Capital’s Cyncado, ADDRI to launch mesothelioma trial of TT-4

AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, operating as Cyncado Therapeutics, announced a non-binding Letter of Intent between Australia’s Asbestos ...